381 related articles for article (PubMed ID: 33649101)
1. Bispecific antibodies targeting mutant
Douglass J; Hsiue EH; Mog BJ; Hwang MS; DiNapoli SR; Pearlman AH; Miller MS; Wright KM; Azurmendi PA; Wang Q; Paul S; Schaefer A; Skora AD; Molin MD; Konig MF; Liu Q; Watson E; Li Y; Murphy MB; Pardoll DM; Bettegowda C; Papadopoulos N; Gabelli SB; Kinzler KW; Vogelstein B; Zhou S
Sci Immunol; 2021 Mar; 6(57):. PubMed ID: 33649101
[TBL] [Abstract][Full Text] [Related]
2. Isolation of T cell receptors targeting recurrent neoantigens in hematological malignancies.
Tubb VM; Schrikkema DS; Croft NP; Purcell AW; Linnemann C; Freriks MR; Chen F; Long HM; Lee SP; Bendle GM
J Immunother Cancer; 2018 Jul; 6(1):70. PubMed ID: 30001747
[TBL] [Abstract][Full Text] [Related]
3. Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations.
Abrams SI; Khleif SN; Bergmann-Leitner ES; Kantor JA; Chung Y; Hamilton JM; Schlom J
Cell Immunol; 1997 Dec; 182(2):137-51. PubMed ID: 9514698
[TBL] [Abstract][Full Text] [Related]
4. Specificity of bispecific T cell receptors and antibodies targeting peptide-HLA.
Holland CJ; Crean RM; Pentier JM; de Wet B; Lloyd A; Srikannathasan V; Lissin N; Lloyd KA; Blicher TH; Conroy PJ; Hock M; Pengelly RJ; Spinner TE; Cameron B; Potter EA; Jeyanthan A; Molloy PE; Sami M; Aleksic M; Liddy N; Robinson RA; Harper S; Lepore M; Pudney CR; van der Kamp MW; Rizkallah PJ; Jakobsen BK; Vuidepot A; Cole DK
J Clin Invest; 2020 May; 130(5):2673-2688. PubMed ID: 32310221
[TBL] [Abstract][Full Text] [Related]
5. Memory T cells of a patient with follicular thyroid carcinoma recognize peptides derived from mutated p21 ras (Gln-->Leu61).
Gedde-Dahl T; Spurkland A; Eriksen JA; Thorsby E; Gaudernack G
Int Immunol; 1992 Nov; 4(11):1331-7. PubMed ID: 1282032
[TBL] [Abstract][Full Text] [Related]
6. Identification of a human CD8+ T lymphocyte neo-epitope created by a ras codon 12 mutation which is restricted by the HLA-A2 allele.
Bergmann-Leitner ES; Kantor JA; Shupert WL; Schlom J; Abrams SI
Cell Immunol; 1998 Aug; 187(2):103-16. PubMed ID: 9732698
[TBL] [Abstract][Full Text] [Related]
7. Targeting a neoantigen derived from a common
Hsiue EH; Wright KM; Douglass J; Hwang MS; Mog BJ; Pearlman AH; Paul S; DiNapoli SR; Konig MF; Wang Q; Schaefer A; Miller MS; Skora AD; Azurmendi PA; Murphy MB; Liu Q; Watson E; Li Y; Pardoll DM; Bettegowda C; Papadopoulos N; Kinzler KW; Vogelstein B; Gabelli SB; Zhou S
Science; 2021 Mar; 371(6533):. PubMed ID: 33649166
[No Abstract] [Full Text] [Related]
8. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
[TBL] [Abstract][Full Text] [Related]
9. HLA binding characteristics and generation of cytotoxic lymphocytes against peptides derived from oncogenic proteins.
Bertazzoli C; Marchesi E; Dermime S; Ravagnani F; Parmiani G; Gambacorti-Passerini C
Tumori; 1997; 83(5):847-55. PubMed ID: 9428921
[TBL] [Abstract][Full Text] [Related]
10. Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARs.
Yarmarkovich M; Marshall QF; Warrington JM; Premaratne R; Farrel A; Groff D; Li W; di Marco M; Runbeck E; Truong H; Toor JS; Tripathi S; Nguyen S; Shen H; Noel T; Church NL; Weiner A; Kendsersky N; Martinez D; Weisberg R; Christie M; Eisenlohr L; Bosse KR; Dimitrov DS; Stevanovic S; Sgourakis NG; Kiefel BR; Maris JM
Nature; 2021 Nov; 599(7885):477-484. PubMed ID: 34732890
[TBL] [Abstract][Full Text] [Related]
11. A scDb-based trivalent bispecific antibody for T-cell-mediated killing of HER3-expressing cancer cells.
Aschmoneit N; Steinlein S; Kühl L; Seifert O; Kontermann RE
Sci Rep; 2021 Jul; 11(1):13880. PubMed ID: 34230555
[TBL] [Abstract][Full Text] [Related]
12. CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas.
Oberst MD; Fuhrmann S; Mulgrew K; Amann M; Cheng L; Lutterbuese P; Richman L; Coats S; Baeuerle PA; Hammond SA
MAbs; 2014; 6(6):1571-84. PubMed ID: 25484061
[TBL] [Abstract][Full Text] [Related]
13. Generation of MANAbodies specific to HLA-restricted epitopes encoded by somatically mutated genes.
Skora AD; Douglass J; Hwang MS; Tam AJ; Blosser RL; Gabelli SB; Cao J; Diaz LA; Papadopoulos N; Kinzler KW; Vogelstein B; Zhou S
Proc Natl Acad Sci U S A; 2015 Aug; 112(32):9967-72. PubMed ID: 26216968
[TBL] [Abstract][Full Text] [Related]
14. HLA-A3 restricted mutant ras specific cytotoxic T-lymphocytes induced by vaccination with T-helper epitopes.
Gjertsen MK; Saeterdal I; Saebøe-Larssen S; Gaudernack G
J Mol Med (Berl); 2003 Jan; 81(1):43-50. PubMed ID: 12545248
[TBL] [Abstract][Full Text] [Related]
15. HLA-E-restricted recognition of human cytomegalovirus by a subset of cytolytic T lymphocytes.
Romagnani C; Pietra G; Falco M; Mazzarino P; Moretta L; Mingari MC
Hum Immunol; 2004 May; 65(5):437-45. PubMed ID: 15172443
[TBL] [Abstract][Full Text] [Related]
16. T-cell responses against products of oncogenes: generation and characterization of human T-cell clones specific for p21 ras-derived synthetic peptides.
Gedde-Dahl T; Eriksen JA; Thorsby E; Gaudernack G
Hum Immunol; 1992 Apr; 33(4):266-74. PubMed ID: 1639630
[TBL] [Abstract][Full Text] [Related]
17. Dendritic cell-based immunotherapy for colon cancer using an HLA-A*0201-restricted cytotoxic T-lymphocyte epitope from tumor-associated antigen 90K.
Hee Lee J; Park MS; Hwang JE; Cho SH; Bae WK; Shim HJ; Kim DE; Chung IJ
Cell Mol Immunol; 2013 May; 10(3):275-82. PubMed ID: 23524651
[TBL] [Abstract][Full Text] [Related]
18. Proteolysis-Targeting Chimeras Enhance T Cell Bispecific Antibody-Driven T Cell Activation and Effector Function through Increased MHC Class I Antigen Presentation in Cancer Cells.
Massafra V; Tundo S; Dietzig A; Ducret A; Jost C; Klein C; Kontermann RE; Knoetgen H; Steegmaier M; Romagnani A; Nagel YA
J Immunol; 2021 Jul; 207(2):493-504. PubMed ID: 34215653
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxic enhancement of a bispecific diabody by format conversion to tandem single-chain variable fragment (taFv): the case of the hEx3 diabody.
Asano R; Ikoma K; Shimomura I; Taki S; Nakanishi T; Umetsu M; Kumagai I
J Biol Chem; 2011 Jan; 286(3):1812-8. PubMed ID: 21097496
[TBL] [Abstract][Full Text] [Related]
20. A human melanoma cell line, recognized by both HLA class I and class II restricted T cells, is capable of initiating both primary and secondary immune responses.
Olsen AC; Fossum B; Kirkin AF; Zeuthen J; Gaudernack G
Scand J Immunol; 1995 Apr; 41(4):357-64. PubMed ID: 7899823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]